DiaMedica Therapeutics, Inc.(NASDAQ : DMAC)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||5.73%||11.77||0.7%||$822.77m|
|VRTX||Vertex Pharmaceuticals, Inc.||3.00%||193.15||1.9%||$543.47m|
|GILD||Gilead Sciences, Inc.||1.59%||67.71||1.0%||$483.39m|
|REGN||Regeneron Pharmaceuticals, Inc.||1.73%||538.95||2.7%||$392.79m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.70%||181.08||2.0%||$334.03m|
|TXG||10X Genomics, Inc.||-1.86%||197.66||0.0%||$175.39m|
|EXAS||EXACT Sciences Corp.||-0.55%||130.25||18.1%||$175.08m|
|BNGO||Bionano Genomics, Inc.||-0.29%||7.23||0.0%||$155.69m|
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.